Navigation Links
Aethlon Medical Releases Shareholder Letter

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.


    To our Shareholders:

    In advance of tomorrow's annual meeting, I wish to thank those
    shareholders who returned proxies supporting measures to re-elect our
    board of directors, reappoint our auditors, and increase the authorized
    shares of our common stock.  The results of your votes will be tabulated
    during our meeting and disclosed shortly thereafter.

    I would also like to take this opportunity to disclose that our
    manufacturing program with Bioserv/NextPharma Technologies is now
    underway, and that infectious disease researchers have provided initial
    verification that our Hemopurifier(R) is able to capture the emerging H1N1
    swine flu virus. We are additionally honored to reestablish a cooperative
    research and development agreement with the U.S. Army Medical Research
    Institute of Infectious Diseases (USAMRIID) that will continue our
    research into treating Ebola and other highly lethal pathogens.

    While I am pleased we have advanced these initiatives, our primary focus
    remains directed towards leveraging our therapeutic opportunity in
    Hepatitis-C care and establishing strategic relationships that will
    maximize long-term economic value for shareholders.  In this regard, we
    are actively pursuing relationships that offer to augment or
    significantly expand our clinical, distribution, and manufacturing
    capabilities.  However, I want to stress the complexity underlying any
    such relationship should not be underestimated.  We face issues that
    include competition between players in the medical device space, scaling
    of manufacturing at feasible costs, and developing appropriate
    distribution channels in a variety of markets.  Additionally, we maintain
    a firm stance that Aethlon Medical shareholders should maintain 100%
    ownership of our Hemopurifier(R) technology.  Regardless of these
    challenges, I am increasingly confident that we will establish
    relationships that provide us the foundation to transition our science
    into a successful business enterprise.

    On behalf of our dedicated team at Aethlon Medical, I thank you for your
    continued support and look forward to meeting those of you who attend
    tomorrow's meeting.

    Very truly yours,

    James A. Joyce
    Chairman, CEO

Certain of the statements within this shareholder letter may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the Company's ability to forge corporate partnerships on terms acceptable to the Company or at all, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.


    Jon Cunningham
    RedChip Companies Inc.
    (407) 644-4256
    (407) 491-4498 -cell or

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300

SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aethlon Medical to Present at Todays Southern California Investor Conference
2. Aethlon Medical Initiates Swine Flu Testing Program
3. Aethlon Medical Announces U.S. Army Agreement
4. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
5. Aethlon Medical Discloses New HIV/AIDS Treatment Data
6. Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
7. Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs
8. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
9. Emergency Medical Transport By Air Carries Risks
10. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
11. Medical Doctor Creates Mantra Medicine Company
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... --  Divoti USA will engrave and process all ... the latest FDA requirements, which stipulates new criteria regarding medical device ... of Medical ID jewelry such as Medical ID Bracelets, can rest ... terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
Breaking Medicine Technology: